Patients using these medications can expect predictable outcomes based on established clinical data
"Our SURMOUNT-5 trial, which is a head-to-head trial comparing tirzepatide (Zepbound) and semaglutide (Wegovy) for the treatment of obesity or overweight with weight-related comorbidities, is expected to read out in 2025," a spokesperson said in an email
Retrieved from Quarenghi, M., Capelli, S., Galligani, G., et al (2025)
Researchers continue to investigate tirzepatide and its role in metabolic health and related biological mechanisms
Regarding oral semaglutide, in contrast to what was shown in a recent Italian retrospective study, it was mainly prescribed in patients with a disease duration of more than 10 years [23]
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1Based Therapies